SPECIALIZED MEDICAL COMPANY
(A SAUDI JOINT STOCK COMPANY)

INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION
FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED 30 JUNE 2026
WITH THE INDEPENDENT AUDITOR'S REVIEW REPORT

SPECIALIZED MEDICAL COMPANY
(A SAUDI JOINT STOCK COMPANY)

INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION
FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED 30 JUNE 2026

INDEX	**PAGE**

Deloitte and Touche & Co.
Chartered Accountants
(Professional Simplified Joint Stock Company)
Paid-up capital ⃁ 5,000,000
Metro Boulevard – Al-Aqiq
King Abdullah Financial District
P.O. Box 213 - Riyadh 11411
Kingdom of Saudi Arabia
C.R. No. 1010600030

Tel: +966 11 5089001
www.deloitte.com

REVIEW REPORT ON INTERIM FINANCIAL INFORMATION

To the Shareholders
Specialized Medical Company
(A Saudi Joint Stock Company)
Riyadh, Kingdom of Saudi Arabia

Introduction

We have reviewed the accompanying interim consolidated statement of financial position of **Specialized Medical Company** ("the Company") **and its subsidiaries** (together "the Group") as at June 30, 2026, and the related interim consolidated statement of profit or loss and other comprehensive income for the three-month and six-month periods then ended, and the related interim consolidated statements of changes in equity and cash flows for the three-month and six-month periods then ended, and the explanatory notes ("the interim financial information"). Management is responsible for the preparation and presentation of this interim financial information in accordance with International Accounting Standard 34 – Interim Financial Reporting (IAS 34) that is endorsed in the Kingdom of Saudi Arabia. Our responsibility is to express a conclusion on this interim financial information based on our review.

Scope of Review

We conducted our review in accordance with International Standard on Review Engagements 2410 – "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" that is endorsed in the Kingdom of Saudi Arabia. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing endorsed in the Kingdom of Saudi Arabia and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim financial information is not prepared, in all material respects, in accordance with IAS 34 that is endorsed in the Kingdom of Saudi Arabia.

Deloitte and Touche & Co.
Chartered Accountants

Waleed bin Moh'd Sobahi
Certified Public Accountant
License No. 378
23 Safar, 1448 AH
August 6, 2026

SPECIALIZED MEDICAL COMPANY
(A SAUDI JOINT STOCK COMPANY)
INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS OF 30 JUNE ,2026

	Notes	As of 30 June,2026 (Unaudited) ⃁	As of December 31,2025 (Audited) ⃁
Assets			
Current assets			
Cash and cash equivalents	3	**130,691,389**	246,702,575
Financial assets at FVTPL	4	**2,263,905**	2,742,437
Trade receivables	5	**461,817,206**	459,343,034
Due from related parties	6	**2,493,191**	2,897,722
Inventories		**34,249,533**	27,158,904
Other current assets		**37,021,800**	46,265,520
Total current assets		**668,537,024**	785,110,192
Non-current assets			
Property and equipment	7	**1,254,412,695**	1,251,608,196
Right-of-use assets	8	**246,448,871**	263,122,530
Investments in equity instruments at FVTPL		**100,000,000**	100,000,000
Total non-current assets		**1,600,861,566**	1,614,730,726
Total assets		**2,269,398,590**	2,399,840,918
Liabilities and equity			
Current liabilities			
Due to related parties	6	**1,168,285**	1,000,447
Trade payables		**110,838,735**	115,494,647
Lease liabilities	8	**42,360,406**	39,655,973
Short-term loans	9	**354,988,292**	246,523,301
Long-term loans - current portion	10	**57,551,020**	57,551,020
Zakat payable	12	**5,448,543**	9,837,798
Other current liabilities		**91,855,521**	81,965,204
Total current liabilities		**664,210,802**	552,028,390
Non-current liabilities			
Lease liabilities	8	**237,036,868**	253,628,195
Long-term loans – non-current portion	10	**200,000,000**	228,775,511
Employees defined benefits liabilities	13	**185,466,092**	177,554,868
Total non-current liabilities		**622,502,960**	659,958,574
Total liabilities		**1,286,713,762**	1,211,986,964
Equity			
Share capital	14	**250,000,000**	250,000,000
Statutory reserve	15	**-**	49,653,238
Retained earnings		**732,684,828**	888,200,716
Total equity		**982,684,828**	1,187,853,954
Total Liabilities and equity		**2,269,398,590**	2,399,840,918

The accompanying notes form an integral part of these interim condensed consolidated financial information, which have been authorized for issue by the Board of Directors on behalf of the Shareholders, and signed on its behalf by:

HANI CHARANI	BASSAM CHAHINE	SULAIMAN AL-RASHID
CFO	CEO	CHAIRMAN

SPECIALIZED MEDICAL COMPANY

(A SAUDI JOINT STOCK COMPANY)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED 30 JUNE 2026

	Notes	For the three-month period ended 30 June		For the six-month period ended 30 June	
		2026 (Unaudited) ⃁	2025 (Unaudited) ⃁	**2026 (Unaudited) ⃁**	2025 (Unaudited) ⃁
Revenue	16	**401,327,431**	379,813,324	**782,001,860**	748,209,174
Cost of revenue		**(301,200,239)**	(281,249,558)	**(590,907,086)**	(561,228,388)
Gross profit		**100,127,192**	98,563,766	**191,094,774**	186,980,786
Selling and marketing expenses		**(2,155,684)**	(2,499,100)	**(5,747,650)**	(8,480,822)
General and administrative expenses		**(42,438,541)**	(47,486,910)	**(88,730,845)**	(89,247,315)
Operating profit		**55,532,967**	48,577,756	**96,616,279**	89,252,649
Finance costs		**(11,696,102)**	(13,015,258)	**(22,051,331)**	(25,163,300)
Other income		**2,823,798**	2,557,980	**5,799,051**	5,172,292
Profit before zakat		**46,660,663**	38,120,478	**80,363,999**	69,261,641
Zakat		**(1,481,410)**	(1,758,772)	**(2,634,940)**	(3,259,599)
Profit for the period		**45,179,253**	36,361,706	**77,729,059**	66,002,042
Earnings per share (EPS)					
Basic and diluted EPS	17	**0.18**	0.15	**0.31**	0.26
Other comprehensive income:					
Items which will not be reclassified subsequently to profit or loss:					
Re-measurement of employees defined benefits liabilities	13	**(1,449,092)**	(372,042)	**(2,898,185)**	(744,085)
Total other comprehensive loss for the period		**(1,449,092)**	(372,042)	**(2,898,185)**	(744,085)
Total comprehensive income for the period		**43,730,161**	35,989,664	**74,830,874**	65,257,957

The accompanying notes form an integral part of these interim condensed consolidated financial information, which have been authorized for issue by the Board of Directors on behalf of the Shareholders, and signed on its behalf by:

HANI CHARANI	BASSAM CHAHINE	SULAIMAN AL-RASHID
CFO	CEO	CHAIRMAN

SPECIALIZED MEDICAL COMPANY
(A SAUDI JOINT STOCK COMPANY)
INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE SIX MONTHS PERIOD ENDED 30 JUNE 2026

	Notes	Share capital ⃁	Statutory reserves ⃁	Retained earnings ⃁	Total equity ⃁
For the six months period ended 30 June 2025					
Balance as of December 31, 2024 (Audited)		250,000,000	49,653,238	527,442,349	827,095,587
Profit for the period		-	-	66,002,042	66,002,042
Total other comprehensive loss		-	-	(744,085)	(744,085)
Total comprehensive income for the period		-	-	65,257,957	65,257,957
Transactions with shareholders in their capacity as owners:					
Dividend distributions refunded	6	-	-	100,000,000	100,000,000
Balance as of 30 June 2025 (Unaudited)		250,000,000	49,653,238	692,700,306	992,353,544
For the six months period ended 30 June 2026					
Balance as of December 31, 2025 (Audited)		**250,000,000**	**49,653,238**	**888,200,716**	**1,187,853,954**
Profit for the period		**-**	**-**	**77,729,059**	**77,729,059**
Total other comprehensive loss		**-**	**-**	**(2,898,185)**	**(2,898,185)**
Total comprehensive income for the period		**-**	**-**	**74,830,874**	**74,830,874**
Transactions with shareholders in their capacity as owners:					
Transfer during the period	15		**(49,653,238)**	**49,653,238**	**-**
Dividends distributions	18	**-**	**-**	**(280,000,000)**	**(280,000,000)**
Balance as of 30 June 2026 (Unaudited)		**250,000,000**	**-**	**732,684,828**	**982,684,828**

The accompanying notes form an integral part of these interim condensed consolidated financial information, which have been authorized for issue by the Board of Directors on behalf of the Shareholders, and signed on its behalf by:

HANI CHARANI	BASSAM CHAHINE	SULAIMAN AL-RASHID
CFO	CEO	CHAIRMAN

SPECIALIZED MEDICAL COMPANY
(A SAUDI JOINT STOCK COMPANY)
INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE SIX MONTHS PERIOD ENDED 30 JUNE 2026

	Notes	For the six-month period ended 30 June	
		2026	2025
		(Unaudited)	(Unaudited)
Cash flows from operating activities		**⃁**	⃁
Profit before zakat		**80,363,999**	69,261,641
Adjustments for non-cash items:			
Depreciation of property and equipment	7	**32,985,101**	30,644,850
Depreciation of right-of-use assets	8	**16,673,659**	14,837,497
Expected credit loss charged		**16,789,999**	9,149,068
Employees defined benefits liabilities charged	13	**7,667,937**	10,204,631
Finance costs		**22,051,331**	25,163,300
Unrealized loss on financial assets at FVTPL		**478,532**	-
Amortization of government grant		**-**	(96,177)
Cash flows from operating activities before changes in working capital items		**177,010,558**	159,164,810
Trade receivables		**(19,264,171)**	(96,286,055)
Due from related parties		**404,531**	(34,452,579)
Inventories		**(7,090,629)**	(7,147,351)
Other current assets		**9,243,720**	8,708,542
Due to related parties		**167,838**	(104,873)
Trade payables		**(4,655,912)**	6,178,846
Other current liabilities		**9,890,317**	50,861,737
Cash generated from operating activities		**165,706,252**	86,923,077
Employees defined benefits liabilities paid		**(7,088,574)**	(7,272,969)
Zakat payable paid		**(7,024,195)**	(4,790,135)
Net cash generated from operating activities		**151,593,483**	74,859,973
Cash flows from investing activities			
Purchase of property and equipment		**(26,684,351)**	(33,537,596)
Additions on projects under progress		**(9,105,249)**	(14,589,714)
Net cash used in investing activities		**(35,789,600)**	(48,127,310)
Cash flows from financing activities			
Dividends paid	18	**(280,000,000)**	-
Due from related parties	6	**-**	100,000,000
Proceeds from short-term loans		**358,464,991**	373,756,507
Repayment of short-term loans		**(250,000,000)**	(475,000,000)
Proceeds from long-term loans		**-**	200,000,000
Repayment of long-term loans		**(28,775,511)**	(28,775,508)
Repayment of government loan		**-**	(2,747,992)
Payment of lease liabilities		**(20,209,429)**	(17,223,012)
Finance cost paid		**(11,295,120)**	(16,899,675)
Net cash (used in) / generated from financing activities		**(231,815,069)**	133,110,320
Net (decrease) / increase in cash and cash equivalents during the period		**(116,011,186)**	159,842,983
Cash and cash equivalents as of January 1		**246,702,575**	92,487,981
Cash and cash equivalents as of 30 June		**130,691,389**	252,330,964

The accompanying notes form an integral part of these interim condensed consolidated financial information, which have been authorized for issue by the Board of Directors on behalf of the Shareholders, and signed on its behalf by:

HANI CHARANI	BASSAM CHAHINE	SULAIMAN AL-RASHID
CFO	CEO	CHAIRMAN

	Notes	For the six-month period ended 30 June	
		2026	2025
		(Unaudited)	(Unaudited)
Non-cash transactions		**⃁**	⃁
Transfer from statutory reserves to retained earnings	15	**49,653,238**	-
Re-measurement of employees defined benefits liabilities	13	**(2,898,185)**	(744,085)
Additions to right-of-use assets and lease liabilities		**-**	23,466,257

The accompanying notes form an integral part of these interim condensed consolidated financial information, which have been authorized for issue by the Board of Directors on behalf of the Shareholders, and signed on its behalf by:

HANI CHARANI	BASSAM CHAHINE	SULAIMAN AL-RASHID
CFO	CEO	CHAIRMAN

1. CORPORATE INFORMATION AND ACTIVITIES

Specialized Medical Company is a Saudi Joint Stock Company (hereinafter referred to as the "Company") operating in the Kingdom of Saudi Arabia under Commercial Registration number 1010123832 dated 24 April 1994 (corresponding 13 Dhul Qa'dah 1414H).

The Company trading symbol is 4019, and its International Securities Identification Number (ISIN) is SA16B0CHUPH2.

The Company operates its activities under the following Ministry of Health Licenses:

Branch name	License number	License date
SMC hospital – King Fahad Road	1410101001200015	May 12, 1999
Diet World center	1410106408400004	Nov 26, 2008
Specialized Medical Center hospital	1410101009700085	April 22, 2014
SMC Medical Clinics	1400090183	Oct 22, 2025

The principal activities of the Company are public hospitals; extended and recovery medical care hospitals; medical operation of hospital; general medical complex; consultancy clinics specialized medical clinics; nutrition centers.

The registered address of the company's office is Building No. 6678, located on King Fahd Road, Al Olaya District, Secondary Number 4405, Postal Code 12311, Riyadh.

This interim condensed consolidated financial information includes the interim condensed financial statements of the Company, its subsidiary and the following branches, which operate under separate commercial registrations:

Branch Name	Commercial Registration No.	Branch Activities	Address	Commercial Registration Date
Specialized Medical Center hospital – SMC 1 - King Fahad Road	1010150227	Public Hospitals	Riyadh	June 24, 1998
Diet World – SMC	1010156585	Nutrition centers; activities of catering services; operation of food concessions at sports and similar facilities; activities of providing catering services for aircrafts	Riyadh	Dec 4, 1999
Specialized Medical Center hospital – SMC 2 - King Abdullah Road	1010413585	Public Hospitals	Riyadh	May 8, 2014
Specialized Medical Company – SMC	1010431691	Public hospitals; extended and recovery medical care hospitals; addiction treatment and rehabilitation hospitals; medical operation of hospital; general medical complexes; consultancy clinics specialized medical clinics.	Riyadh	Mar 23, 2015
Specialized Medical Company – SMC 3 – Northern Ring Road	1010851377	Public hospitals; medical operation of hospital	Riyadh	Dec 28, 2022

2. MATERIAL ACCOUNTING POLICY INFORMATION

The following outlines certain information of material accounting policies adopted by the Group's management in the preparation of this condensed consolidated interim financial information. The material accounting policies, estimates, and assumptions used in preparing this condensed consolidated interim financial information are consistent with those applied in the preparation of the Group's audited annual financial statements as of and for the year ended 31 December 2025, unless otherwise stated.

2-1 <u>Basis of Preparation of the condensed consolidated interim financial information</u>

The condensed consolidated interim financial information has been prepared in accordance with the International Accounting Standard "Interim Financial Reporting" (International Accounting Standard No. 34) as adopted in the Kingdom of Saudi Arabia, along with other standards and pronouncements issued and approved by the Saudi Organization for Chartered and Professional Accountants, hereinafter referred to as the "International Financial Reporting Standards (IFRS).

The condensed consolidated interim financial information has been prepared under the historical cost principle, except where otherwise stated.

The condensed consolidated interim financial information has been prepared on the going concern basis.

The condensed consolidated interim financial information has been prepared on the accrual basis of accounting.

The Saudi Riyal (⃁) is the presentation currency of the condensed consolidated interim financial information and represents the Group's functional currency. All amounts are rounded to the nearest Saudi Riyal (⃁), unless otherwise stated.

2-2 <u>Basis of Consolidation of the condensed consolidated interim financial information</u>

The condensed consolidated interim financial information includes the condensed interim financial information of the Company and its controlled subsidiaries. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. The Group controls an investee if and only if the Group has:

- Power over the investee (i.e. existing rights that give it the current ability to direct the relevant activities of the investee).
- Exposure, or rights, to variable returns from its involvement with the investee.
- The ability to use its power over the investee to affect its returns.

When the Group has less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including:
- The contractual arrangement with the other vote holders of the investee.
- Rights arising from other contractual arrangements.
- The Group's voting rights and potential voting rights.

The Group re-assesses whether it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control mentioned above.

Profit or loss and each component of other comprehensive income (OCI) are attributed to the equity holders of the parent and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. When necessary, adjustments are made to the financial statements of subsidiaries to align their accounting policies with those of the Group. All intra-group assets and liabilities, equity, income, expenses, and profits or losses arising from transactions between the Group and its subsidiaries are eliminated in full. The Company and its subsidiaries follow the same reporting period.

The consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control. The revenues and expenses of a subsidiary, or of a disposed subsidiary during the period, are included in the condensed consolidated statement of profit or loss and other comprehensive income from the date the Group obtains control until the date the Group ceases to have control over the subsidiary.

2. MATERIAL ACCOUNTING POLICY INFORMATION (continued)

2-2 Basis of Consolidation of the condensed consolidated interim financial information (continued)

The Company accounts for business combinations using the acquisition method when control is transferred to the Company. The consideration transferred at the acquisition date is generally measured at fair value, as are the identifiable net assets acquired. Any excess of the acquisition cost over the fair value of the identifiable net assets acquired is recognized as goodwill in the condensed consolidated statement of financial position.

The Company has the following subsidiaries:

Name	Country of Incorporation	Activities	Ownership percentage 2026	2025
International Specialized Food Company	Saudi Arabia	Food and catering services	100%	100%
Al-Mukhattis Al-Sahi Medical Company	Saudi Arabia	Hospitals for the treatment, rehabilitation and medical operation of addicts	51%	51%

As of the financial reporting date, Al-Mukhattis Al-Sahi Medical Company has not commenced operations. Additionally, the capital contribution required for the subsidiary has not been paid.

2-3 Changes in accounting policy and disclosures

(A) New and amended standards and interpretations issued and adopted by the Group in the financial year beginning on 1 January 2026

Standard/ interpretation	Description	Effective from periods beginning on or after
Amendments to IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures	Under the amendments, certain financial assets including those with ESG-linked features could now meet the SPPI criteria, provided that their cash flows are not significantly different from an identical financial asset without such a feature. The IASB has amended IFRS 9 to clarify when a financial asset or a financial liability is recognized and derecognized and to provide an exception for certain financial liabilities settled using an electronic payment system.	1 January 2026
Amendments to IFRS 9 and IFRS 7 Contracts referencing Nature-dependent Electricity	Contracts Referencing Nature-dependent Electricity amends IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures to more faithfully reflect the effects of contracts referencing nature-dependent electricity on an entity's financial statements.	1 January 2026
Annual improvements to IFRS – Volume 11	Annual improvements are limited to changes that either clarify the wording in an Accounting Standard or correct relatively minor unintended consequences, oversights or conflicts between the requirements in the Accounting Standards. The 2024 amendments are to the following standards: IFRS 1 First-time Adoption of international Financial Reporting Standards; IFRS 7 Financial Instruments: Disclosures and its accompanying Guidance on implementing IFRS 7; IFRS 9 Financial Instruments; IFRS 10 Consolidated Financial Statements; and IAS 7 Statement of Cash Flows.	1 January 2026

The amendment listed above did not have any material impact on the Group's consolidation of the condensed consolidated interim financial information.

2. MATERIAL ACCOUNTING POLICY INFORMATION (continued)

2-3 Changes in accounting policy and disclosures (continued)

(B) New and amended standards and interpretations issued but not yet effective and not early adopted

Standard/ interpretation	Description	Effective from periods beginning on or after
Amendments to IFRS 10 and IAS 28- Sale or Contribution of Assets between an Investor and its Associate or Joint Venture	Partial gain or loss recognition for transactions between an investor and its associate or joint venture only apply to the gain or loss resulting from the sale or contribution of assets that do not constitute a business as defined in IFRS 3 Business Combinations and the gain or loss resulting from the sale or contribution to an associate or a joint venture of assets that constitute a business as defined in IFRS 3 is recognized in full.	Effective date deferred indefinitely
Amendments to IFRS 10 and IAS 28- Sale or Contribution of Assets between an Investor and its Associate or Joint Venture	IFRS 18 provides guidance on items in statement of profit or loss classified into five categories: operating; investing; financing; income taxes and discontinued operations It defines a subset of measures related to an entity's financial performance as 'management-defined performance measures' ('MPMs'). The totals, subtotals and line items presented in the primary financial statements and items disclosed in the notes need to be described in a way that represents the characteristics of the item. It requires foreign exchange differences to be classified in the same category as the income and expenses from the items that resulted in the foreign exchange differences.	1 January 2027
IFRS 19, Subsidiaries without Public Accountability: Disclosures	IFRS 19 allows eligible subsidiaries to apply IFRS Accounting Standards with the reduced disclosure requirements of IFRS 19. A subsidiary may choose to apply the new standard in its consolidated, separate or individual financial statements provided that, at the reporting date, it does not have public accountability, and its parent produces consolidated financial statements under IFRS Accounting Standards.	1 January 2027
IFRS 18, Presentation and Disclosure in Financial Statements *	IFRS 18 provides guidance on items in statement of profit or loss classified into five categories: operating; investing; financing; income taxes and discontinued operations It defines a subset of measures related to an entity's financial performance as 'management-defined performance measures' (MPMs'). The totals, subtotals and line items presented in the primary financial statements and items disclosed in the notes need to be described in a way that represents the characteristics of the item. It requires foreign exchange differences to be classified in the same category as the income and expenses from the items that resulted in the foreign exchange differences.	1 January 2027

2. MATERIAL ACCOUNTING POLICY INFORMATION (continued)

2-3 Changes in accounting policy and disclosures (continued)

* IFRS 18 "Presentation and Disclosure in Financial Statements" will replace IAS 1 "Presentation of Financial Statements" and is effective for annual reporting periods beginning on or after 1 January 2027. The Group has not adopted the Standard early.

IFRS 18 introduces significant changes to the presentation of the consolidated statement of profit or loss and its accompanying disclosures, the most significant of which are:

- Mandatory classification of income and expense items into three new principal categories in the statement of profit or loss: operating, investing and financing, to improve comparability between entities.
- A requirement for entities to present two new defined subtotals (Subtotals) in the statement of profit or loss, namely "operating profit" and "profit before financing and income tax".
- New disclosure requirements for "Management-defined performance measures", including their reconciliation to the most directly comparable subtotal specified by IFRS Accounting Standards, and an explanation of how they are used.
- Enhanced principles for the aggregation and disaggregation of items in the financial statements and notes, to limit the presentation of immaterial or dissimilar items within an "other" line item.
- Consequential amendments to IAS 7 "Statement of Cash Flows", the most significant of which is the adoption of "operating profit" as the mandatory starting point for presenting operating cash flows using the indirect method.

Assessment of the expected impact on the Group's consolidated financial statements

The Group's management has performed an initial assessment of the impact of adopting IFRS 18 on the consolidated financial statements, and this assessment remains in progress as at the date of issuance of this interim condensed consolidated financial information, and additional changes to the expected impact may arise as implementation activities progress and further regulatory guidance becomes available.

As part of this assessment, the Group's management identified the Group's main business activities in accordance with the requirements of IFRS 18 and concluded that the Group does not have a main business activity of investing in assets and/or providing financing to customers. The Group's main business activities comprise the provision of healthcare and nutrition services (Note 1). Accordingly, revenue and expenses arising from these activities will be classified and presented within the operating category and included in the operating profit or loss subtotal, in accordance with the requirements of IFRS 18.

The Standard does not change the recognition or measurement basis, or the timing of recognition, of assets, liabilities, income or expenses, and is therefore not expected to have an impact on the Group's net profit or total equity, as its effect is limited to presentation and disclosure and does not affect the Group's existing measurement or recognition bases.

Based on the current stage of the assessment, Group management expects the principal impact of adoption to arise in the following areas:

(a) Structure of the statement of profit or loss

The Standard requires the classification of all revenues and expenses items into three categories, and the presentation of two new mandatory subtotals:

• Operating: All the Group's operating income and expenses, including those relating to its principal business activities, will be presented within the operating category. In addition, bank charges and other fees that are not related to raising finance or changes in interest rates will be reclassified and presented within the operating category.

• Investing: Income and expenses arising from assets that generate a return largely independent of the Group's other resources will be presented within the investing category. Accordingly, interest income on short-term deposits, and realized and unrealized gains or losses arising from financial assets measured at fair value through profit or loss, will be presented within the investing category.

• Financing: Income and expenses arising solely from transactions undertaken to obtain financing will be presented within the financing category. These include borrowings, financing facilities, lease liabilities, and defined benefit obligations for employees.

• Two new mandatory subtotals will be presented: "operating profit" and "Profit Before Financing and Zakat and Income Taxes".

This classification does not result in any change to the measurement basis, and its impact is limited to the manner of classification and presentation.

2. MATERIAL ACCOUNTING POLICY INFORMATION (continued)

2-3 <u>Changes in accounting policy and disclosures (continued)</u>

(b) Management-defined performance measures (MPMs)

These are subtotals of revenues and expenses that are not required by IFRS Accounting Standards, used by Group management in its public communications outside the financial statements to communicate its view of performance. The Standard requires disclosure of these measures within a single note, including:

- A reconciliation of each measure to the most directly comparable subtotal specified by IFRS Accounting Standards.
- The reasons for using the measure and how it is calculated, include its income tax and zakat effect.
- An explanation of any changes to the measure from one period to another.

The Group is currently identifying the public communications that should be considered in determining management-defined performance measures, noting that these measures relate to the same reporting period covered by the financial statements. Accordingly, the management-defined performance measures the Group will disclose following the adoption of IFRS 18 will be determined based on the public communications the Group issues in respect of its first reporting period for 2027.

(c) Aggregation and disaggregation principles

The Standard strengthens the principles governing the aggregation and disaggregation of information in the financial statements and notes and provides guidance on the labelling and description of items presented in the primary financial statements or disclosed in the notes.

Group management is currently assessing the basis for aggregating items with similar and dissimilar characteristics; based on this assessment, items will be presented in the primary financial statements that provide useful, structured summaries. Group management is also assessing items currently classified under the label “other”, and more descriptive labels will be used instead.

(d) Consequential amendments

IFRS 18 introduces consequential amendments to IAS 7 “Statement of Cash Flows”, requiring entities to use the new “operating profit” subtotal as the starting point for preparing the statement of cash flows when presenting operating cash flows using the indirect method.

Group management currently uses profit for the year/period before zakat as the starting point for the reconciliation to cash flows from operating activities; because of the new starting point, certain reconciling items included within this statement will change. The consequential amendments also provide specific guidance on the classification of cash flows relating to interest and dividends.

Except as noted above, there are no other IFRS Accounting Standards, as endorsed in the Kingdom of Saudi Arabia, or amendments to issued standards, or other interpretations issued by the Saudi Organization for Chartered and Professional Accountants (SOCPA) that are issued but not yet effective for the first time for the Group’s financial period beginning 1 January 2026, that are expected to have a material impact on the Group’s condensed consolidated interim financial information.

3. CASH AND CASH EQUIVALENTS

	As of 30 June,2026 (Unaudited)	As of December 31,2025 (Audited)
	⃁	⃁
Cash at Banks – Current Accounts	**130,147,224**	46,088,145
Cash on Hand	**544,165**	614,430
Cash at Banks – Short-Term Deposit Accounts	**-**	200,000,000
	130,691,389	246,702,575

The Group management's assessment of the impact of applying International Financial Reporting Standard (IFRS) 9 on all bank balances (short-term deposit accounts, and current accounts) is not material. Accordingly, no impact was recognized for the periods ended 30 June 2026 and 2025. The Group's management has decided to maintain these balances with financial institutions that have high credit ratings.

4. FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS (FVTPL)

	As of 30 June,2026 (Unaudited)	As of December 31,2025 (Audited)
	⃁	⃁
Balance as of the beginning of the period / year	**2,742,437**	-
Additions during the period / year	**-**	7,072,566
Unrealized losses during the period / year	**(478,532)**	(1,566,383)
Realized gains during the period / year	**-**	1,175,205
Disposals during the period / year	**-**	(3,938,951)
Balance as of the beginning of the period / year	**2,263,905**	2,742,437

Financial assets at fair value through profit or loss consist of securities traded on the Saudi Stock Exchange – Saudi Tadawul Group – and are measured at fair value. The fair value is determined based on the closing prices traded on the Saudi Stock Exchange – Saudi Tadawul Group.

5. TRADE RECEIVABLES

	As of 30 June,2026 (Unaudited)	As of December 31,2025 (Audited)
	⃁	⃁
Trade receivables	**509,507,729**	490,243,558
Less: Allowance of expected credit losses *	**(47,690,523)**	(30,900,524)
	461,817,206	459,343,034

Movement of allowance of expected credit losses *	**As of 30 June,2026 (Unaudited)**	As of December 31,2025 (Audited)
	⃁	⃁
Balance as of the beginning of the period / year	**30,900,524**	18,265,205
Charged during the period / year	**16,789,999**	12,635,319
Balance as of the ending of the period / year	**47,690,523**	30,900,524

6. TRANSACTIONS AND BALANCES WITH RELATED PARTY

Related parties include major shareholders, companies owned by them, members of the Board of Directors, and their relatives. During its ordinary course of business, the Group conducted transactions with related parties in accordance with terms approved by the Group's management.

Name of Related Party	Relationship
Saudi Bonyan Company	Owned by one of the major shareholders
Advance food Company	Owned by one of the major shareholders
Food Aroma Company	Owned by one of the major shareholders
Bonyan Reit Fund	Owned by one of the major shareholders
Invention Code Company	Owned by a close family member of a major shareholder
Danah Real Estate Company	Owned by a close family member of a major shareholder
Abdulrahman Saad Al-Rashid & Sons Company	Major shareholder
Abdullah Saad Al Rashid & Sons Company	Major shareholder
Rashid Saad Al Rashid & Sons Company	Major shareholder
Saudi Company for Electrical and Mechanical Works (SSEM)	Common Board Membership
Members of the Board of Directors, their close family members, and those related to them	Family Members
Adeem Al Sahra Trading Company *****	Owned by one of the shareholders
Cotton Experts Company *****	Owned by one of the shareholders
Snow Bright Laundry Company *****	Owned by one of the shareholders
Khalid Medical Clinic Company *****	Owned by a close family member of a shareholder
Resaleh Mubashera Trading Est *****	Owned by a close family member of a shareholder
Wakillk for law and legal advice Company *****	Owned by a close family member of a shareholder
Dr. Khalid Al Sebaiay *****	Shareholder
Dr. Mohammad Saleh Al Konbaz *****	Shareholder
Al-Thomad Trading Company **	Previous relationship: Major shareholder Current relationship: One of its owners is a member of the Board of Directors

***** Effective 1 January 2026, the parties referred to above are no longer classified as related parties, as they no longer meet the definition of related parties in accordance with IAS 24 Related Party Disclosures under IFRS. They are also neither affiliated nor owned by any major shareholders. These parties have been disclosed for comparative information purposes only, as they were classified as related parties in prior periods. Accordingly, the comparative information reflects the previous classification, while the current period information is presented based on the updated classification in line with IFRS.

6.TRANSACTIONS AND BALANCES WITH RELATED PARTY - (continued)

** On 18 May 2026 (corresponding to 1 Dhu al-Hijjah 1447H), the Group's management received a notification from Al Thomad Trading Company, in its capacity as one of the Company's major shareholders, regarding the reorganization of its ownership interest in the Company, amounting to 35,344,925 shares, representing 14.13% of the Company's share capital. The reorganization was carried out through the transfer of these shares to the investment portfolios of the individual owners of Al Thomad Trading Company. Accordingly, effective from that date, Al Thomad Trading Company is no longer classified as a major shareholder; however, it continues to be classified as a related party, as one of its owners—who is a member of the Group's Board of Directors—holds a direct ownership interest in it. Consequently, the nature of the relationship has been updated from "major shareholder" to "an entity owned by a member of the Board of Directors.

Significant transactions and the related amounts	**For the six-month period ended 30 June**	
	2026	2025
	(Unaudited)	(Unaudited)
	⃁	⃁
Rent and lease liabilities payments	**9,439,106**	8,253,447
Purchases and services	**2,078,622**	7,032,346
Revenue	**1,443,747**	1,008,941
Other revenue	**914,164**	1,271,900
Expenses incurred on behalf	**100,460**	268,659
Construction works for projects under progress	-	1,700,000
Advance payments	-	1,348,364
Amounts due from shareholders related to dividends reversal *	-	200,000,000
Expenses incurred on behalf of shareholders related to IPO expenses **	-	33,992,715

* The Ordinary General Assembly of the Group at their meeting held May 22, 2025 (corresponding 24 Dhu Al-Qi'dah 1446H) decided the following:

Reverse the Board of Directors' resolution dated January 21, 2025 (corresponding 21 Rajab 1446H) regarding the distribution of interim dividends to shareholders amounting to ⃁ 100,000,000 based on their respective shareholding in the capital. These dividends were distributed and paid on January 26, 2025 (corresponding 26 Rajab 1446H).

Reverse the Board of Directors' resolution dated November 5, 2024 (corresponding 3 Jumada Al-Awwal 1446H) and ratified by the General Assembly of the Group on December 15, 2024 (corresponding 14 Jumada Al-Thani 1446H) regarding the distribution of interim dividends to shareholders amounting to ⃁ 100,000,000 based on their respective shareholding in the capital. These dividends were distributed and paid on December 19, 2024 (corresponding 18 Jumada Al-Thani 1446H) and December 21, 2024 (corresponding 20 Jumada Al-Thani 1446H).

Each shareholder required to repay these dividends to the Group's accounts by no later than June 30, 2025 (corresponding 5 Muharram 1447H).

On June 30, 2025 (corresponding 5 Muharram 1447H) an amount of ⃁ 200,000,000 was collected from shareholders through a bank transfer to the Group's account.

** On July 8, 2025 (corresponding 13 Muharram 1447H) an amount of ⃁ 37,588,227 was collected from shareholders through a bank transfer to the Group's account related to IPO expenses incurred on behalf of them up to date of transfer.

Compensation of key management personnel of the group	**For the six-month period ended 30 June**	
	2026	2025
	(Unaudited)	(Unaudited)
	⃁	⃁
Short term employment benefits	**5,616,451**	4,734,023
Board of Directors' remuneration	**825,000**	275,000
Post-employment benefits	**345,431**	1,055,543
	6,786,882	6,064,566

Key management personnel of the Group comprise the members of the Board of Directors and senior executive officers responsible for planning, directing, and monitoring the Group's activities.

6.TRANSACTIONS AND BALANCES WITH RELATED PARTY - (continued)

Due from related parties	As of 30 June,2026 (Unaudited) ⃁	As of December 31,2025 (Audited) ⃁
Saudi Bunyan Company	**957,811**	857,351
Members of the Board of Directors, their close family members, and those related to them	**926,360**	763,089
Saudi Company for Electrical and Mechanical Works (SSEM)	**609,020**	-
Advance food Company	**-**	1,271,900
Abdulrahman Saad Al-Rashid & Sons Company	**-**	5,382
	2,493,191	2,897,722

Due to related parties	As of 30 June,2026 (Unaudited) ⃁	As of December 31,2025 (Audited) ⃁
Food Aroma Company	**1,161,484**	592,231
Al-Thomad Travel and Tourism Company	**6,801**	142,772
Code Invention Company	**-**	46,952
Cotton Experts Company	**-**	181,291
Adeem Al Sahra Trading Company	**-**	37,201
	1,168,285	1,000,447

7. PROPERTY AND EQUIPMENT

Reconciliation of carrying amounts	As of 30 June,2026 (Unaudited) ⃁	As of December 31,2025 (Audited) ⃁
Carrying amount as of beginning of the period / year	**1,251,608,196**	1,259,153,397
Additions during the period / year	**35,789,600**	94,459,364
Net of disposals during the period / year	**-**	(39,547,988)
Depreciation charge during the period / year	**(32,985,101)**	(62,456,577)
Carrying amount as of the end of the period / year	**1,254,412,695**	1,251,608,196

Category-wise carrying amounts	As of 30 June,2026 (Unaudited) ⃁	As of December 31,2025 (Audited) ⃁
Buildings and renovation	**664,410,164**	662,156,995
Lands	**298,208,864**	298,208,864
Medical equipment	**153,662,497**	161,779,553
Projects under progress *	**88,417,866**	79,312,617
General equipment	**29,758,354**	28,455,332
Computers and software	**14,714,785**	16,245,110
Furniture and fixtures	**4,851,602**	4,972,473
Motors vehicles	**388,563**	477,252
	1,254,412,695	1,251,608,196

* During the period ended 30 June,2026 an amount of ⃁ 4,608,026 (30 June,2025: ⃁ 5,705,853) was capitalized as borrowing cost.

Allocation of depreciation expense in the condensed consolidated statement of profit or loss and other comprehensive income	**For the six-month period ended 30 June** 2026 (Unaudited) ⃁	2025 (Unaudited) ⃁
Cost of revenue	**30,050,099**	27,865,855
General and administrative expenses	**2,935,002**	2,778,995
	32,985,101	30,644,850

8. RIGHT OF USE ASSETS AND LEASE LIABILITIES

Reconciliation of the carrying amount of right-of-use assets	As of 30 June,2026 (Unaudited) ⃁	As of December 31,2025 (Audited) ⃁
Cost		
Balance as of the beginning of the period / year	**462,422,153**	370,582,402
Additions during the period / year	**-**	91,839,751
Balance as of the ending of the period / year	**462,422,153**	462,422,153
Accumulated depreciation		
Balance as of the beginning of the period / year	**199,299,623**	168,704,117
Additions during the period / year	**16,673,659**	30,595,506
Balance as of the ending of the period / year	**215,973,282**	199,299,623
Net book value	**246,448,871**	263,122,530
Details of the net book value by type of lease contract		
Hospital lands, buildings and outpatient's clinic buildings	**230,371,108**	243,947,574
Administrative office buildings and staff accommodation	**13,502,457**	15,834,497
Medical equipment and devices	**2,575,306**	3,340,459
	246,448,871	263,122,530

	For the six-month period ended 30 June	
Allocation of depreciation expense in the condensed consolidated statement of profit or loss and other comprehensive income	**2026 (Unaudited) ⃁**	2025 (Unaudited) ⃁
Cost of revenue	**15,718,807**	13,995,092
General and administrative expenses	**954,852**	842,405
	16,673,659	14,837,497

Expenses related to short-term and low-value lease contracts for the period ended 30 June,2026 an amount of ⃁ 169,018 (30 June,2025: ⃁ 128,828)

Movement of lease liabilities	As of 30 June,2026 (Unaudited) ⃁	As of December 31,2025 (Audited) ⃁
Balance as of the beginning of the period / year	**293,284,168**	225,528,207
Additions during the period / year	**-**	91,839,751
Finance costs during the period / year	**6,322,535**	10,135,875
Paid during the period / year	**(20,209,429)**	(34,219,665)
Balance as of the ending of the period / year	**279,397,274**	293,284,168
Current portion of lease liabilities	**42,360,406**	39,655,973
Non-current portion of lease liabilities	**237,036,868**	253,628,195

Present value of lease liabilities	As of 30 June,2026 (Unaudited) ⃁	As of December 31,2025 (Audited) ⃁
Minimum future lease liabilities	**383,991,550**	404,200,979
Less: unamortized finance costs	**(104,594,276)**	(110,916,811)
Present value of minimum lease liabilities	**279,397,274**	293,284,168
Current portion of lease liabilities	**42,360,406**	39,655,973
Non-current portion of lease liabilities	**237,036,868**	253,628,195

The Group has recognised assets and liabilities for its finance leases, which include various types of contracts such as buildings, land, accommodation and office rentals, medical equipment, etc. The terms of these contracts range from 2 to 20 years.

9. SHORT-TERM LOANS

The Group obtained Shariah-compliant bank facilities from local commercial banks at an interest rate plus SAIBOR to finance the working capital requirements. The value of the withdrawal until 30 June, 2026 amounted to ⃁ 354,988,292 (December 31, 2025: ⃁ 246,523,301).

10. LONG-TERM LOANS

Movement of long-term loans	**As of 30 June,2026 (Unaudited) ⃁**	As of December 31,2025 (Audited) ⃁
Balance as of the beginning of the period / year	**286,326,531**	143,877,551
Additions during the period / year	**-**	200,000,000
Paid during the period / year	**(28,775,511)**	(57,551,020)
Balance as of the ending of the period / year	**257,551,020**	286,326,531
Current portion of long-term loans	**57,551,020**	57,551,020
Non-current portion of long-term loans	**200,000,000**	228,775,511

The Group obtained Shariah-compliant bank facilities from local commercial banks at an interest rate plus SAIBOR to finance projects under construction.

11. GOVRNMENT GRANTS AND LOAN

Movement of government loan	**As of 30 June,2026 (Unaudited) ⃁**	As of December 31,2025 (Audited) ⃁
Balance as of the beginning of the period / year	**-**	2,747,992
Paid during the period / year	**-**	(2,747,992)
Balance as of the ending of the period / year	**-**	-

The Group received an interest-free government loan for medical equipment and furniture. The loan was secured by a mortgage over land and a building. The final installment was paid for on February 27, 2025, and the mortgage was released.

Movement of government loan	**As of 30 June,2026 (Unaudited) ⃁**	As of December 31,2025 (Audited) ⃁
Balance as of the beginning of the period / year	**-**	96,177
Amortization during the period / year	**-**	(96,177)
Balance as of the ending of the period / year	**-**	-

The government grant represents the difference between the fair value and the carrying amount of interest-free loan obtained from the Ministry of Finance to finance the purchase of medical equipment and furniture. All conditions for the grant have been fulfilled by the Group.

12. ZAKAT PAYABLE

Movement of zakat payable	**As of 30 June,2026 (Unaudited) ⃁**	As of December 31,2025 (Audited) ⃁
Balance as of the beginning of the period / year	**9,837,798**	8,351,552
Additions during the period / year	**2,634,940**	6,273,672
Paid during the period / year	**(7,024,195)**	(4,787,426)
Balance as of the ending of the period / year	**5,448,543**	9,837,798

Zakat Status

Zakat declarations have been submitted to the Zakat, Tax and Customs Authority (the Authority) for all years up to 31 December 2025. The Group has obtained the final assessments up to year 2018 and for the year 2024 and is still awaiting the final assessments for the years 2019 to 2023 and for the year 2025 from the Authority.

13. EMPLOYEES DEFINED BENEFITS LIABILITIES

Movement of employees defined benefits liabilities	**As of 30 June,2026 (Unaudited) ⃁**	As of December 31,2025 (Audited) ⃁
Balance as of the beginning of the period / year	**177,554,868**	159,552,201
Additions during the period / year	**14,999,798**	32,589,667
Paid during the period / year	**(7,088,574)**	(14,587,000)
Balance as of the ending of the period / year	**185,466,092**	177,554,868

	For the six-month period ended 30 June	
Details of additions to employees defined benefits liabilities	**2026 (Unaudited) ⃁**	2025 (Unaudited) ⃁
Current service cost	**7,667,937**	10,204,631
Interest cost	**4,433,676**	3,571,085
Expenses charged to the condensed consolidated statement of profit or loss	**12,101,613**	13,775,716
Actuarial losses arising from remeasurement	**2,898,185**	744,085
Expenses charged to the condensed consolidated statement of other	**2,898,185**	744,085
Total additions to employees defined benefits liabilities	**14,999,798**	14,519,801

14. SHARE CAPITAL

The Company’s share capital as of 30 June,2026 & December 31, 2025, amounted to ⃁ 250,000,000 consisting of 250,000,000 shares fully paid and issued shares of ⃁ 1 each. Holders of these shares are entitled to dividends as declared from time to time and entitled to one vote per share at general assembly meeting.

15. STATUTORY RESERVE

The statutory reserve included in the interim condensed consolidated statement of financial position as of December 31, 2025, was required under the Company’s previous by-laws. However, following amendments to the Company's by-laws during the year ended December 31, 2024, the requirement to set aside a statutory reserve has been removed. The Board of Directors, in its meeting held on July 29, 2025, (Corresponding 4 Safar 1447H), recommended to the General Assembly to transfer the balance of the statutory reserve amounting ⃁ 49,653,238 to retained earnings balance. The Extraordinary General Assembly, in its meeting held on 6 January 2026 (corresponding to 17 Rajb 1447H), approved this recommendation, resulting in the full balance being transferred to retained earnings.

16. REVENUE

The Group primarily generates revenue from contracts with customers from:

1- Relating to inpatient and outpatient medical services; and
2- Sale of medicines - pharmaceutical; and
3- Sale of food and a catering service.

	For the three-month period ended 30 June		**For the six-month period ended 30 June**	
	2026 (Unaudited) ⃁	2025 (Unaudited) ⃁	**2026 (Unaudited) ⃁**	2025 (Unaudited) ⃁
Relating to inpatient and outpatient medical services	**321,495,095**	311,666,388	**631,628,722**	610,281,094
Medicines - Pharmaceutical	**72,054,377**	63,551,132	**136,010,406**	128,590,446
Food and catering services	**7,777,959**	4,595,804	**14,362,732**	9,337,634
	401,327,431	379,813,324	**782,001,860**	748,209,174

17. EARNINGS PER SHARE

	For the three-month period ended 30 June		**For the six-month period ended 30 June**	
	2026 (Unaudited) ⃁	2025 (Unaudited) ⃁	**2026 (Unaudited) ⃁**	2025 (Unaudited) ⃁
Profit for the period attributable to owners of the Company	**45,179,253**	36,361,706	**77,729,059**	66,002,042
Divided by: Weighted average number	**250,000,000**	250,000,000	**250,000,000**	250,000,000
	0.18	0.15	**0.31**	0.26

18. APPROVED AND PROPOSED DIVIDENDS

The Board of Directors, in its meeting held on November 3, 2025 (corresponding to 12 Jumada I 1447H), recommended to the General Assembly the distribution of exceptional cash dividends to shareholders amounting to ⃁ 200,000,000. The Extraordinary General Assembly, at its meeting held on 6 January 2026 (corresponding to 17 Rajb 1447H), approved this recommendation. And the amount of ⃁ 200,000,000 was paid and distributed to the shareholders.

The Board of Directors, at its meeting held on 8 March 2026 (corresponding to 19 Ramadan 1447H), recommended to the General Assembly the distribution of cash dividends to shareholders amounting to ⃁ 80,000,000 for the financial year ended 31 December 2025. The Ordinary General Assembly, at its meeting held on 17 May 2026 (corresponding to 30 Dhu al-Qi'dah 1447H), approved this recommendation, and an amount of ⃁ 80,000,000 was paid and distributed to shareholders.

19. COMMITMENTS AND CONTINGENT LIABILITIES

Capital commitments related to projects under constructions	**As of 30 June,2026 (Unaudited) ⃁**	As of December 31,2025 (Audited) ⃁
Project - SMC 3	**18,190,357**	19,951,364
Project - SMC 4	**81,306,917**	82,326,917
	99,497,274	102,278,281
Letters of Guarantee		
Bank Letters of Guarantee	**15,855,368**	17,195,754

20. SEGMENT INFORMATION

As the Group operates in the Kingdom of Saudi Arabia, for management purposes, the Group is organized into business units based on its products and services, and it has two reportable segments. Operating segments are identified based on the internal reports submitted to the Chief Operating Decision Maker (CODM) for operational decision making. CODM has been identified as the person responsible for allocating resources to the segments and assessing the performance of each segment. Revenue and the segment's gross profit are consistent measures used within the Group. The principal identified segments are Medical Services, Pharmacies, and Others.

The following table presents segment information (assets, liabilities, revenue, and gross profit) for each of the business segments.

	Medical Services ⃁	**Pharmacies, and Others ⃁**	**Total ⃁**
For the period ended 30 June, 2026	**(Unaudited)**		
Revenue	**631,628,722**	**150,373,138**	**782,001,860**
Gross profit	**156,111,021**	**34,983,753**	**191,094,774**
For the year ended 30 June 2025 (Unaudited)			
Revenue	610,281,094	137,928,080	748,209,174
Gross profit	151,476,676	35,504,110	186,980,786
As of 30 June 2026 (Unaudited)			
Total assets	**2,192,345,168**	**77,053,422**	**2,269,398,590**
Total liabilities	**1,217,760,840**	**68,952,922**	**1,286,713,762**
As of December 31, 2025 (Audited)			
Total assets	2,329,994,062	69,846,856	2,399,840,918
Total liabilities	1,158,158,044	53,828,920	1,211,986,964

21. RECLASSIFICATION OF COMPARATIVE FINANCIAL INFORMATION

Certain figures for the comparison period have been reclassified to conform to the presentation in the current period.

22. SUBSEQUENT EVENTS

On 25 July 2026 (corresponding to 11 Safar 1448H),Al-Mukhattis Al-Sahi Medical Company, a subsidiary of the Group, signed a contract with the Ministry of Health of the Kingdom of Saudi Arabia for the management and operation of SABIC Specialized Behavioral Care Hospital. The project is expected to commence commercial operations during the second quarter of 2027.

Except for the event described above, there were no events, after 30 June 2026, and occurring before the date of the approval of the interim condensed consolidated financial information that are expected to have a significant impact on this interim condensed consolidated financial information.

23. BOARD OF DIRECTORS APPROVAL

These the interim condensed consolidated financial information were approved by the Board of Directors on behalf of the Shareholders on August 04 ,2026 (corresponding 21 Safar 1448H) and signed on its behalf by:

HANI CHARANI	BASSAM CHAHINE	SULAIMAN AL-RASHID
CFO	CEO	CHAIRMAN